Skip to content

Motor Cortex Stimulation in the Treatment of Chronic Neuropathic Pain: Real-World Data on Long-Term Outcomes, Predictors of Response, and Safety.

Oct 2026 · Neuromodulation (Malden, Mass.) · 0 citations
Medicine

Abstract

Objectives

Motor cortex stimulation (MCS) has been used for chronic neuropathic pain for over 35 years, yet long-term efficacy and safety data remain extremely limited. This study aimed to present real-world data on the long-term outcomes, predictors of response, and safety of MCS in clinical practice.

Materials And Methods

A retrospective analysis was conducted on 20 patients (median age 52.5 years) who underwent epidural MCS implantation at a single neurosurgical center between 2004 and 2014. Indications included neuropathic pain lasting more than three months with an intensity >5 on the Numeric Rating Scale (NRS) refractory to conservative therapy. Preoperative transcranial magnetic stimulation (TMS) and functional magnetic resonance imaging with neuronavigation were used for electrode targeting. Pain intensity was assessed using a questionnaire based on the Brief Pain Inventory. Stimulation efficacy was defined as ≥50% pain reduction at the last follow-up. Statistical analysis employed nonparametric methods (Wilcoxon signed-rank test). The median follow-up was 11 years.

Results

At last follow-up, median pain intensity decreased from 8 to 4 points on the NRS (p < 0.05). Long-term pain reduction ≥50% was achieved in 14 of 19 patients (73.7%). One patient was excluded from the long-term efficacy analysis due to system explantation for infection three months postoperatively. Two patients (10%) experienced a loss of efficacy over time. TMS demonstrated a positive predictive value of 71.43% but a negative predictive value of only 33.33% in predicting MCS efficacy. Infectious complications leading to system explantation occurred in two patients (10%). No seizures, hematomas, or permanent neurologic deficits were observed.

Conclusions

MCS provides clinically significant long-term pain reduction in 70% of patients with chronic neuropathic pain, alongside subjectively improved quality of life and reduced analgesic requirements. A single ineffective TMS session should not preclude MCS implantation because the negative predictive value is low. Larger randomized controlled trials are warranted to verify these findings.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.